Which has the lower trailing P/E, AMGN or VRTX?

AMGN has the lower trailing P/E: AMGN trades at 27.30 and VRTX at 31.90. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, AMGN or VRTX?

Over the past five years, VRTX grew revenue faster — AMGN at a 8.39% CAGR versus VRTX at 13.57%.

Does AMGN or VRTX pay a bigger dividend?

AMGN pays a dividend (2.23% yield), while VRTX has no payments in the available dividend history.

Is AMGN or VRTX more profitable?

VRTX runs the higher net margin — AMGN at 22.93% versus VRTX at 34.89%.

How have AMGN and VRTX total returns compared?

Over the past 10 years, AMGN delivered 13.04% and VRTX delivered 18.77% annualized total return. Past performance doesn't predict future results.

Amgen Inc. (AMGN) vs Vertex Pharmaceuticals Incorporated (VRTX)

A side-by-side comparison of Amgen Inc. and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 23, 2026. Differences are shown without an overall score or investment verdict.

AMGN

Amgen Inc.

$237.11B

$439.33HealthcareAt close: Aug 21, 2026, 4:00 PM ET

VRTX

Vertex Pharmaceuticals Incorporated

$139.10B

$548.05HealthcareAt close: Aug 21, 2026, 4:00 PM ET

Total return — AMGN vs VRTX

growth of $100 · dividends reinvested · last 10y

AMGN +240.8% (+13.0%/yr)VRTX +464.5% (+18.9%/yr)VRTX compounded faster over this window

AMGN VRTX

AMGN vs VRTX: by the numbers

•AMGN is the larger company ($237.11B vs $139.10B market cap).
•AMGN trades at the lower trailing earnings multiple (27.30 vs 31.90 P/E), one valuation lens rather than an overall verdict.
•VRTX converts more revenue to profit (34.89% vs 22.93% net margin).
•VRTX grew revenue faster over the past five years (13.57% vs 8.39% CAGR).
•AMGN pays a dividend (2.23% yield), while VRTX has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	AMGN	VRTX
P/E ratio	27.30	31.90
Forward P/E	19.04	29.24
P/S ratio	6.27	11.10
P/B ratio	20.45	6.92
EV / EBITDA	18.71	26.71
FCF yield	4.26%	2.71%

Profitability

Metric	AMGN	VRTX
Gross margin	72.65%	86.04%
Operating margin	33.18%	38.59%
Net margin	22.93%	34.89%
ROE	74.80%	21.76%
ROIC	14.22%	17.33%

Dividends

Metric	AMGN	VRTX
Dividend yield	2.23%	N/A
Payout ratio	68.39%	N/A

Growth (annualized)

Metric	AMGN	VRTX
Revenue CAGR (5Y)	8.39%	13.57%
EPS CAGR (5Y)	2.94%	8.17%
FCF CAGR (5Y)	-3.91%	16.39%
Total return CAGR (5Y)	18.08%	22.84%

Frequently asked

Which has the lower trailing P/E, AMGN or VRTX?: AMGN has the lower trailing P/E: AMGN trades at 27.30 and VRTX at 31.90. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, AMGN or VRTX?: Over the past five years, VRTX grew revenue faster — AMGN at a 8.39% CAGR versus VRTX at 13.57%.
Does AMGN or VRTX pay a bigger dividend?: AMGN pays a dividend (2.23% yield), while VRTX has no payments in the available dividend history.
Is AMGN or VRTX more profitable?: VRTX runs the higher net margin — AMGN at 22.93% versus VRTX at 34.89%.
How have AMGN and VRTX total returns compared?: Over the past 10 years, AMGN delivered 13.04% and VRTX delivered 18.77% annualized total return. Past performance doesn't predict future results.

Go deeper

Full AMGN analysis Full VRTX analysis Interactive comparison tool

Dig into the metrics

Amgen P/E ratio Vertex Pharmaceuticals P/E ratio Amgen dividend yield Amgen ROE Vertex Pharmaceuticals ROE Amgen operating margin Vertex Pharmaceuticals operating margin Amgen revenue growth Vertex Pharmaceuticals revenue growth Amgen free cash flow Vertex Pharmaceuticals free cash flow

Amgen & Vertex Pharmaceuticals appear in these rankings

Highest Dividend Yield Stocks Highest ROE Stocks Highest Operating Margin Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 23, 2026.